Sphingosine pathway modulating compounds for the treatment of cancers

Abstract

The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

What is claimed is: 
     
         1 . A method for treating a hematological cancer in a mammalian subject, comprising the step of:
 administering to a mammalian subject in need of treatment for the hematological cancer an effective amount of ozanimod or a pharmaceutically acceptable salt thereof,   wherein the hematological cancer is Acute lymphoblastic leukemia (ALL); Acute myelogenous leukemia (AML); Chronic lymphocytic leukemia (CLL); Chronic myelogenous leukemia (CML); Acute monocytic leukemia (AMoL); a Hodgkin's lymphoma, or a Non-Hodgkin's lymphoma.   
     
     
         2 . The method of  claim 1 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject. 
     
     
         3 . The method of  claim 1 , wherein the mammalian subject is a human. 
     
     
         4 . The method of  claim 3 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject.